Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01024660 | The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil | EARLY_PHASE1 | COMPLETED | 155 | — | — | Dec 1, 2009 | Jan 1, 2011 | Feb 8, 2011 | 18 | Canada, Peru +2 |
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | 5 mg Donepezil (first 14 days), 10 mg Donepezil (next 70 days) |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Donepezil | DRUG | 5 mg capsule, orally, once daily, first 14 days of treatment |
| Placebo to match Aricept | DRUG | Placebo capsule, orally, 84 days of treatment |
Inclusion Criteria: * Clinical diagnosis of probable AD according to NINCDS-ADRDA criteria. * The patient should live with an appropriate caregiver at home, or in a community dwelling. A caregiver should be capable of accompanying the patient to clinic visits or attending study visits in the patien...